NY-WUNDERKIND
Wunderkind, the leading performance marketing solution that delivers guaranteed revenue and performance for brands, publishers and advertisers, announced the appointment of Bill Ingram, a proven marketing technology leader, as Chief Executive Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230302005559/en/
Former Adobe and Cheetah Digital executive Bill Ingram named CEO of leading performance marketing solution Wunderkind. (Photo: Business Wire)
Ingram brings over 30 years of experience scaling tech start-ups, leading enterprise SaaS organization advancement, and driving product development and growth. Before joining Wunderkind, Ingram served as President and Chief Product Officer at Cheetah Digital, driving the global innovation and advancement of next generation B2C marketing automation solutions. Previously, Ingram was Vice President and General Manager at Adobe, overseeing the organization’s Analytics Cloud worldwide business for over 10 years. Ingram previously held leadership roles with several SaaS organizations, including Sybase and Omniture, which was acquired by Adobe for $1.8B.
In his role as CEO, Ingram will establish and drive Wunderkind’s strategic direction and product expansion in support of increasing customer engagement for the world’s leading brands. He will focus on taking Wunderkind’s products and services to new levels, while maintaining an industry leading revenue guarantee. Additionally, he will work to advance Wunderkind’s product suite for leading publishers to further engage consumers in an impactful, non-intrusive way that fosters increased brand visibility and qualified engagement. Ingram will lead the team towards ensuring Wunderkind’s solutions continue to help advertisers reach their priority audiences while delivering a quality user experience across a network of premium publishers. Furthermore, he will concentrate on leading the Wunderkind team to eclipsing its over 34% year-over-year revenue increase realized last year.
“Wunderkind has achieved exponential growth by delivering undeniable marketing performance and increased revenue for the world’s most renowned eCommerce brands, who are constantly competing to attract, retain and convert valued customers,” said CEO Bill Ingram. “Wunderkind has proven that channels once perceived as top- and middle-of-funnel can be transformed into significant revenue drivers. I look forward to leading the company’s all-star team as we embark upon a new chapter of strategic innovation and proliferation.”
Ingram’s appointment comes as Wunderkind is poised for continued acceleration in 2023 on the heels of major milestones in 2022, which included: a $76M in Series C financing led by Neuberger Berman; 34% year-over-year revenue gain; and the opening of offices in Australia, Canada, and the Netherlands to further its global reach.
“In a fiercely competitive eCommerce landscape, marketers are under tremendous pressure to deliver verifiable ROI for every dollar spent. Wunderkind's pioneering solutions stand superior to all other solutions in our industry, assisting countless brands in driving provable revenue while building lasting customer loyalty,” said Stephen Collins, Wunderkind’s Board Chairman. “We are confident that Bill’s proven leadership, industry expertise, and success in scaling global technology organizations will realize a new era of growth and success for Wunderkind’s customers, partners and employees alike.”
During the 2022 holiday season, despite a challenging macroeconomic climate, Wunderkind was pivotal in helping its clients achieve more than $1B in directly attributable revenue. The company recently added a host of premium publishers and global retailers to its client roster, including; Rag & Bone, Refinery29, JLo Beauty, Uniqlo, e.l.f. cosmetics, Swatch, Outdoor Voices, See's Candy.
About Wunderkind
Wunderkind is a leading performance marketing solution that drives guaranteed revenue for brands, publishers, and advertisers. As first-party data becomes central to efficient growth, Wunderkind enables brands to identify their website visitors on an individual level and deliver more of their highest-performing, one-to-one messages through websites, emails, texts, and ads than otherwise possible. Wunderkind drives $5 billion annually in directly attributable revenue for brands like Uniqlo, Refinery29, Sonos, and HelloFresh, often ranking as a top three performance channel in their own analytics platforms. Discover how Wunderkind can drive efficient growth for your brand by visiting wunderkind.co.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005559/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom